|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
ferric nitrilotriacetate inhibits the reaction [Asbestos, Crocidolite results in increased expression of ABCB1 protein]; ferric nitrilotriacetate inhibits the reaction [Razoxane results in increased expression of ABCB1 protein] |
CTD |
PMID:18385176 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ABCC1 mRNA |
CTD |
PMID:18617210 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ABCC2 mRNA |
CTD |
PMID:18617210 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ABCC4 mRNA |
CTD |
PMID:18617210 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Anxa2 |
annexin A2 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of ANXA2 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of BAX mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of BBC3 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bik |
BCL2-interacting killer |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of BIK mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Cald1 |
caldesmon 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CALD1 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 4:63,265,781...63,446,936
Ensembl chr 4:63,265,942...63,446,932
|
|
G |
Canx |
calnexin |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CANX protein |
CTD |
PMID:16908007 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Casp12 |
caspase 12 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CASP12 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP3 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP3 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP3 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP3 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP8 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP8 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP9 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP9 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP9 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP9 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein; chrysin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]; geraniol inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein]; Quercetin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein] |
CTD |
PMID:9667754 PMID:15198074 PMID:18684806 PMID:21907755 PMID:23194824 PMID:30098279 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CCND1 mRNA; ferric nitrilotriacetate results in increased expression of CCND1 protein |
CTD |
PMID:18055543 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CD44 mRNA; ferric nitrilotriacetate results in increased expression of CD44 protein |
CTD |
PMID:18055543 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd47 |
Cd47 molecule |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CD47 mRNA |
CTD |
PMID:9119739 |
|
NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CDKN1A mRNA |
CTD |
PMID:23208426 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
decreases expression |
EXP |
ferric nitrilotriacetate results in decreased expression of CHRM1 mRNA |
CTD |
PMID:19490752 |
|
NCBI chr 1:205,567,046...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
decreases expression |
EXP |
ferric nitrilotriacetate results in decreased expression of CHRM2 mRNA |
CTD |
PMID:19490752 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
EXP |
ferric nitrilotriacetate results in increased expression of COL1A1 protein ethylisopropylamiloride inhibits the reaction [ferric nitrilotriacetate results in increased expression of COL1A1 protein] |
CTD |
PMID:11159895 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cygb |
cytoglobin |
multiple interactions |
EXP |
CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]; CYGB protein results in decreased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid] |
CTD |
PMID:16581302 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein; [Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein; allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]] |
CTD |
PMID:12086689 PMID:17034788 PMID:21352821 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of FOS mRNA |
CTD |
PMID:10381381 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of FOSL1 mRNA; ferric nitrilotriacetate results in increased expression of FOSL1 protein |
CTD |
PMID:18055543 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
EXP |
ferric nitrilotriacetate results in decreased activity of G6PD protein |
CTD |
PMID:9667754 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of GCLC mRNA |
CTD |
PMID:18617210 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity multiple interactions |
EXP |
ferric nitrilotriacetate results in decreased activity of GSR protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein]; Quercetin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of GSR protein] |
CTD |
PMID:9667754 PMID:15198074 PMID:30098279 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gtse1 |
G-2 and S-phase expressed 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of GTSE1 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 protein; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein] |
CTD |
PMID:21907755 PMID:30098279 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
ferric nitrilotriacetate inhibits the reaction [Asbestos, Crocidolite results in increased activity of HIF1A protein]; ferric nitrilotriacetate inhibits the reaction [Razoxane results in increased activity of HIF1A protein] |
CTD |
PMID:18385176 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP ISO |
ferric nitrilotriacetate results in increased expression of HMOX1 mRNA |
CTD |
PMID:18617210 PMID:19490752 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of HSP90AA1 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Il24 |
interleukin 24 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of IL24 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO EXP |
ferric nitrilotriacetate results in increased expression of IL6 protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of IL6 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of IL6 protein] ferric nitrilotriacetate results in increased expression of IL6 mRNA |
CTD |
PMID:15781289 PMID:19490752 PMID:23194824 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of JUN mRNA; ferric nitrilotriacetate results in increased expression of JUN protein |
CTD |
PMID:18055543 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein |
CTD |
PMID:17034788 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Krt8 |
keratin 8 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein |
CTD |
PMID:17034788 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of MCM3 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT2 protein binds to Cadmium] |
CTD |
PMID:22001350 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mt3 |
metallothionein 3 |
decreases response to substance |
ISO |
MT3 protein results in decreased susceptibility to ferric nitrilotriacetate |
CTD |
PMID:12383939 |
|
NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of MYC mRNA; ferric nitrilotriacetate results in increased expression of MYC protein |
CTD |
PMID:18055543 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
ISO |
ferric nitrilotriacetate affects the localization of NFE2L2 protein |
CTD |
PMID:18617210 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of NFKB1 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of NFKB1 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
ferric nitrilotriacetate inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; ferric nitrilotriacetate inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein]; ferric nitrilotriacetate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of NOS2 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of NOS2 protein]; chrysin inhibits the reaction [ferric nitrilotriacetate results in increased expression of NOS2 protein]; ferric nitrilotriacetate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; ferric nitrilotriacetate promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] |
CTD |
PMID:11461780 PMID:11746204 PMID:12490132 PMID:23194824 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of NQO1 mRNA; ferric nitrilotriacetate results in increased expression of NQO1 protein |
CTD |
PMID:18617210 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions increases activity |
EXP |
[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein; Active Hexose Correlated Compound inhibits the reaction [[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein]; Vitamin E inhibits the reaction [ferric nitrilotriacetate results in increased activity of ODC1 protein] |
CTD |
PMID:9667754 PMID:14623030 PMID:15949125 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PCK1 mRNA |
CTD |
PMID:16960379 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PCNA protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PCNA protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA protein] |
CTD |
PMID:21907755 PMID:23194824 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Phlda3 |
pleckstrin homology-like domain, family A, member 3 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PHLDA3 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions increases activity increases expression |
ISO |
Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased activity of PLAU mRNA]; Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased expression of PLAU mRNA] |
CTD |
PMID:17571974 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PLK2 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947
|
|
G |
Pola1 |
DNA polymerase alpha 1, catalytic subunit |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of POLA1 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr X:58,034,617...58,348,612
Ensembl chr X:58,034,619...58,348,536
|
|
G |
Ppia |
peptidylprolyl isomerase A |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PPIA protein |
CTD |
PMID:16908007 |
|
NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein]; chrysin inhibits the reaction [ferric nitrilotriacetate results in increased expression of PTGS2 protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein] |
CTD |
PMID:23194824 PMID:30098279 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptprb |
protein tyrosine phosphatase, receptor type, B |
decreases expression |
EXP |
ferric nitrilotriacetate results in decreased expression of PTPRB mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 7:51,953,375...52,034,751
Ensembl chr 7:51,930,015...52,034,748
|
|
G |
Ptprz1 |
protein tyrosine phosphatase, receptor type Z1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PTPRZ1 mRNA; ferric nitrilotriacetate results in increased expression of PTPRZ1 protein |
CTD |
PMID:18055543 |
|
NCBI chr 4:51,397,316...51,595,220
Ensembl chr 4:51,397,601...51,595,218
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased localization of RELA protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased localization of RELA protein] |
CTD |
PMID:23194824 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rpl19 |
ribosomal protein L19 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of RPL19 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr10:83,022,503...83,026,030
Ensembl chr10:83,019,257...83,052,112
|
|
G |
Rprm |
reprimo, TP53 dependent G2 arrest mediator homolog |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of RPRM mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 3:38,539,581...38,540,998
Ensembl chr 3:38,539,581...38,540,998
|
|
G |
Rps13 |
ribosomal protein S13 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of RPS13 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 1:170,572,925...170,575,355
Ensembl chr 1:170,572,921...170,575,355
|
|
G |
Rps15 |
ribosomal protein S15 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of RPS15 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 7:9,416,003...9,417,442
Ensembl chr 7:9,416,004...9,417,450
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
decreases expression |
ISO |
ferric nitrilotriacetate results in decreased expression of SLC11A2 mRNA |
CTD |
PMID:11925462 |
|
NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
decreases expression |
ISO |
ferric nitrilotriacetate results in decreased expression of SLC40A1 mRNA |
CTD |
PMID:11925462 |
|
NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
ferric nitrilotriacetate inhibits the reaction [Dimethylnitrosamine results in decreased expression of SOD1 protein] |
CTD |
PMID:15842777 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Ssrp1 |
structure specific recognition protein 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of SSRP1 mRNA |
CTD |
PMID:8844983 |
|
NCBI chr 3:70,124,371...70,134,481
Ensembl chr 3:70,118,655...70,134,482
|
|
G |
Tgfa |
transforming growth factor alpha |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of TGFA mRNA; ferric nitrilotriacetate results in increased expression of TGFA protein |
CTD |
PMID:8340253 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA] |
CTD |
PMID:16581302 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of TGFB2 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16581302 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO EXP |
ferric nitrilotriacetate results in increased expression of TNF protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of TNF protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of TNF protein] |
CTD |
PMID:15781289 PMID:23194824 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein] |
CTD |
PMID:21907755 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of TXN protein |
CTD |
PMID:15834431 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression increases methylation |
EXP |
ferric nitrilotriacetate results in decreased expression of TXNIP protein ferric nitrilotriacetate results in increased methylation of TXNIP promoter |
CTD |
PMID:15834431 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ubd |
ubiquitin D |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of UBD mRNA |
CTD |
PMID:23208426 |
|
NCBI chr20:1,385,487...1,387,438
Ensembl chr20:1,385,864...1,408,639 Ensembl chr20:1,385,864...1,408,639
|
|